$SNEX

Rotsztain Diego sold $2.2M of SNEX

Rotsztain Diego (Chief Governance/Legal Officer) sold 29,995 shares of StoneX Group Inc. (SNEX) at $74.32 ($2.23M total) on 2026-07-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rotsztain Diego
Published Jul 24, 2026, 12:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
high confidence
Mentioned
$SNEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale size, price, and total value, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the sale for sentiment monitoring, but the 10b5-1 framing makes it less actionable for fundamental repricing.

03

What to watch

The filing does not disclose reasons for the sale, and the net holdings after the transaction (55,500 shares) suggest the insider did not exit entirely.

Relevance 5/10Novelty 3/10Timing: New Form 4 filed 2026-07-23, covering a sale executed 2026-07-22.

Background

The article is a SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralHigh confidence
Context

StoneX Group insider Diego Rotsztain sold 29,995 shares on 2026-07-22 for about $2.23M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely short-lived.

Evidence & confidence

The filing is a Form 4 insider sale, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal risk management or diversification, which some traders may interpret as mild caution.

Key entities

  • StoneX Group Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Diego Rotsztain

    Chief Governance/Legal Officer who sold shares.

  • 10b5-1 plan

    Pre-arranged plan that typically reduces the informational content of insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.